Odyssey Health, Inc. (ODYY) Building on Safety Profile of

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
361
Odyssey Health, Inc. (ODYY) Building on Safety Profile of Concussion Pharmaceutical Treatment, PRV-002, in its Phase I MAD Clinical Trial

- Odyssey successfully completed the second Cohort of its Phase I MAD clinical trial, proving the safety profile of its concussion pharmaceutical treatment, PRV-002
- This study built on the success of Cohort I, where the drug was well tolerated and proved safe, with no severe adverse events reported
- The company’s Phase I Single Ascending Dose (“SAD”) cohorts of the clinical trial closed on July 12, 2022, proving the drug was safe and well tolerated. Results from this study were well received by the SRC, who also expressed their optimism for Odyssey’s completion of the MAD portion of its Phase I trial and subsequent Phase II and III studies
- Odyssey looks to offer a viable solution for treating concussions, regarded as a significant “unmet” medical need. It also looks to capitalize on a growing market projected to be valued at $8.9 billion by 2027

Odyssey Health (OTC: ODYY), an enterprise committed to developing unique, life-enhancing medical products, marked a successful close of the second Cohort of its Phase I Multi-Day Ascending Dosing (“MAD”) clinical trial (https://nnw.fm/4mlmr ).

While making the announcement, Odyssey’s Chief Executive Officer (“CEO”), Michael Redmond, expressed how pleased he was with the safety profile of the company’s concussion pharmaceutical treatment, PRV-002.

“As we come close to completing the Phase I trial, I am very pleased with the safety profile of our concussion pharmaceutical treatment, PRV-002,” he noted.

“I’m equally pleased that the intranasal drug/device combination has functioned nicely and has been easy to operate in the clinical setting,” he added.

Odyssey’s trial involved administering its novel drug to treat concussions, PRV-002, to healthy human subjects to determine drug safety. A total of 40 healthy subjects took part in the study. In Cohort I, eight patients received a low dose of the drug, and in Cohort II, patients received a high dose of the drug. The second Cohort reflected the success of the first, where the drug was well tolerated and proved safe with no severe adverse events reported.

On July 12, 2022, Odyssey announced the successful completion of its Phase I Single Ascending Dosing (“SAD”) clinical trial, which also involved administering PRV-002. This study proved that the drug was safe and well tolerated and would lay the foundation for the currently-ongoing MAD clinical study (https://nnw.fm/F3SeJ ).

At the time, Dallas Hack, the Managing Director (“MD”) and member of the Safety Review Committee (“SRC”), reckoned:

“After reviewing the data from Cohort III and completing the SAD analysis, I have strong confidence that PRV-002 will continue to show safety during the Multiple Ascending Dosing (‘MAD’) portion of the Phase I clinical trial where subjects are treated once daily for five straight days.”

Philip Ryan, the MD and Principle Investor for Nucleus Network, noted:

“PRV-002 was well-tolerated throughout the SAD portion of the Phase I trial. The SRC has confidence about the safety of the intranasal delivery of PRV-002.”

“We look forward to completing MAD portion of the Phase I trial and assisting Odyssey with their Phase II/III design to determine the efficacy of PRV-002 for concussed patients,” he added.

Odyssey, so far, has lived up to its expectations and those of the SRC, proving the overall safety of its novel drug. With concussions representing a significant “unmet” medical need affecting millions worldwide, the company is inching closer to offering a viable solution that will benefit patients. In addition, it is positioning itself to take advantage of an industry projected to be valued at $8.9 billion by 2027, up from $6.9 billion in 2020 (https://nnw.fm/5IaMe ).

Odyssey is currently in the process of selecting clinical sites and developing the Investigator’s Brochure for the Phase II trial. As of July 2022, the company was still in discussions with military training sites for Phase II and III clinical trials, which it hopes to kick off later this year.

For more information, visit the company’s website at www.OdysseyHealthInc.com.

NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://nnw.fm/ODYY

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer


Odyssey Group Intl Inc (ODYY) Stock Research Links

ODYY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vector's Peptide Pact Needs Proof Before Any Payday

Updated Category News Views 140

A famous orthopedic name can open doors, but it cannot manufacture clinical evidence. That is the plain reality behind Vector Science and Therapeutics' new collaboration with the Andrews Research & Education Foundation. Dr. James Andrews carries enormous credibility in sports medicine, earned across more than five decades of work. For Vector, that association matters. For...

Continue Reading
Zunyi’s History Tour Carries China’s Story Overseas

Updated Category News Views 84

China’s national story does not travel overseas by accident; it gets carried by visitors, monuments, rail lines, rivers and carefully chosen questions. The Zunyi News and Media Center report follows Tayyab, a Pakistani PhD student in aerospace engineering at Peking University, as he heads from Beijing to Zunyi, Guizhou, carrying a copy of Edgar Snow’s Red Star Over...

Continue Reading
Lithium's Next Leg Depends on Storage, Not EV Hype

Updated Category News Views 67

Grid batteries are quietly becoming lithium’s second engine, and that matters more than another flashy electric-vehicle sales headline. The market is projected to rise from $40.87 billion in 2026 to $57.77 billion by 2031, a 7.2% compound annual growth rate. Respectable growth, certainly. But this is not a straight line, and anybody treating a five-year market forecast...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 267

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 102

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading
Precision Metal Forming Is Industry's Quiet Backbone

Updated Category News Views 72

A fraction of a millimeter can turn a perfectly good industrial part into an expensive headache. That unglamorous reality sits at the center of Michele Caulfield's discussion of precision metal forming for HelloNation, and it deserves more attention than it usually gets. Investors watching manufacturing tend to chase flashy automation headlines, big aerospace orders, or...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 144

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
Tronox Pushes Back on Creditor Restructuring Chatter Firmly

Updated Category News Views 20

A Creditor Rumor Is Not a Restructuring Plan Two creditor groups hiring law firms can make a stock chart look like it stepped on a rake, but it is not the same thing as a debt workout. That distinction is the whole point of Tronox Holdings' November 18 update. A November 17 Wall Street Journal report said two groups of creditors had retained firms described as...

Continue Reading
Miami I20 Tests Appetite for Long-Term U.S. Capital

Updated Category News Views 124

Five days in a Miami airport hotel may not sound like the machinery of national investment policy, yet the guest list for the inaugural I20 Summit is serious enough to make capital markets sit up. From December 11 through 15, the Sovereign Wealth Fund Institute plans to bring sovereign funds, pensions, endowments, family offices, business leaders and U.S....

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 159

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading

Top 5 Most Recently Viewed Articles

San Jose Workers Ready to Strike Amid Contract Woes

Updated Category News Views 87

Strike Looms Over San Jose City Workers Can't say I blame these San Jose city workers. They're at their wits' end, caught in what's feeling like an endless round of negotiations that just aren't getting anywhere. July 29 saw hundreds of city employees packed into Strike School sessions, seriously gearing up for what's looking like a showdown with city officials. Ain't a...

Continue Reading
Foot Health Revolution: Custom Orthotic Insoles Lead Market Surge

Updated Category News Views 70

Understanding the Custom Foot Orthotic Insoles Market Growth The Custom Foot Orthotic Insoles Market is experiencing remarkable growth driven by a series of key factors. The increasing awareness surrounding foot health, including the benefits of personalized support, plays a pivotal role in this expansion. As more individuals recognize the advantages provided by custom...

Continue Reading
Columbus McKinnon Announce Regular Dividend of $0.07

Updated Category News Views 117

Columbus McKinnon Corporation Declares Quarterly Dividend Columbus McKinnon Corporation (NASDAQ: CMCO), an established leader in intelligent motion solutions for material handling, has made a significant announcement regarding its dividend. The Board of Directors has affirmed their commitment to shareholders by declaring a regular quarterly dividend of $0.07 per common...

Continue Reading
System Integration Market Set for 13.5% Growth by 2033

Updated Category News Views 74

Understanding the Growth of the System Integration Market The global system integration market plays a vital role in the technology sector by enabling the smooth integration of various subsystems, software applications, and IT infrastructures into a unified operational framework. This market is essential for businesses looking to boost productivity, streamline processes,...

Continue Reading
Zoom Earnings Report: Analysts Revise Forecasts and Outlook

Updated Category News Views 157

Anticipation Builds for Zoom's Earnings Announcement Zoom is on the brink of dropping its fourth-quarter earnings results; brace yourself for some market action come Wednesday, February 25. This isn't just any quarterly call; it could show whether Zoom still has the magic touch or if it's leaning hard on its video-chat crutch amid growing competition and changing...

Continue Reading